AgomAb Therapeutics

CEO Tim Knotnerus
CEO Tim Knotnerus
Belgium | Funding: $237M (+)

Website: https://agomab.com/

AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.